Analyst Ratings For Omeros Corporation (NASDAQ:OMER)
Today, MED reiterated its Reduce rating on Omeros Corporation (NASDAQ:OMER).
There are 1 sell ratings, 4 hold ratings, 4 buy ratings, 0 strong buy ratings on the stock.
The current consensus rating on Omeros Corporation (NASDAQ:OMER) is Hold with a consensus target price of $27.0013 per share, a potential 37.55% upside.
Some recent analyst ratings include
- 7/23/2018-MED Reiterated Rating of Reduce.
- 7/12/2018-Seaport Global Securities initiated coverage with a Buy rating.
- 5/16/2018-Wedbush Reiterated Rating of Neutral .
- 3/26/2018-WBB Securities Reiterated Rating of Buy.
- 3/2/2018-Needham & Company LLC was Downgraded by analysts at Needham & Company LLC from a “Buy ” rating to a ” Hold” rating. They now have a $9.01 price target on the stock.
Recent Insider Trading Activity For Omeros Corporation (NASDAQ:OMER)
Omeros Corporation (NASDAQ:OMER) has insider ownership of 12.10% and institutional ownership of 46.06%.
- On 7/12/2018 Marcia S Kelbon, VP, sold 4,277 with an average share price of $21.48 per share and the total transaction amounting to $91,869.96.
- On 5/15/2018 Michael A Jacobsen, VP, sold 23,792 with an average share price of $23.80 per share and the total transaction amounting to $566,249.60.
- On 1/3/2018 Michael A Jacobsen, VP, sold 1,020 with an average share price of $22.45 per share and the total transaction amounting to $22,899.00.
- On 6/16/2017 Michael A Jacobsen, VP, sold 12,000 with an average share price of $24.95 per share and the total transaction amounting to $299,400.00.
- On 6/15/2017 Michael A Jacobsen, VP, sold 24,000 with an average share price of $21.20 per share and the total transaction amounting to $508,800.00.
- On 4/12/2017 Thomas J Cable, Director, sold 3,000 with an average share price of $16.49 per share and the total transaction amounting to $49,470.00.
- On 12/7/2016 Gregory A Md Demopulos, CEO, sold 306,124 with an average share price of $10.66 per share and the total transaction amounting to $3,263,281.84.
About Omeros Corporation (NASDAQ:OMER)
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Its clinical programs include OMS721 that is in Phase III clinical trial for treating immunoglobulin A (IgA) nephropathy, hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA), and atypical hemolytic uremic syndrome (aHUS); and in Phase II clinical trial to treat IgA nephropathy, membranous nephropathy, lupus nephritis, and complement component glomerulopathy. The company's clinical programs also consists of OMS824, which is in Phase II clinical trial for treating Huntington's diseases and schizophrenia; and OMS405 that is in Phase II clinical trial to treat opioids, nicotine, and alcohol addiction. Its preclinical programs comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders; and OMS906 to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. The company's preclinical programs also include MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HCT-TMA, and age-related macular degeneration; MASP-3-small-molecule inhibitors used for the treatment of PNH and other alternative pathway disorders; G protein-coupled receptor (GPCR) platform, including GPR174 and other Class A orphan GPCRS for treating CNS, metabolic, CV, oncologic, musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal and other disorders. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.
Recent Trading Activity for Omeros Corporation (NASDAQ:OMER)
Shares of Omeros Corporation closed the previous trading session at 19.63 −0.42 2.09% with shares trading hands.
